Novartis Receives FDA Approval for Kesimpta in Pediatric Multiple Sclerosis

Novartis today announced that the FDA has approved Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis in children and adolescents aged 10 years and older. The approval was based on results from the Phase 3 NEOS trial, which demonstrated significant reductions in annualized relapse rates and MRI lesion activity in pediatric patients.